Neurocrine Biosciences (NBIX) earnings, Jul 30, 2026: EPS +31%, stock +2.6%
In brief
Neurocrine Biosciences reported on Jul 30, 2026. Earnings per share changed +31% year over year, 15.7% below the estimate; revenue +39%. The stock opened with a −1.0% gap and closed the day +2.6% (Jul 30, 2026). The stock is now 14.2% below its 52-week high, +3.9% over 12 months. Next report: Feb 11, 2027.
EPS vs estimate−15.7%
EPS, YoY+31%
Revenue, YoY+39%
Gap · day−1.0% · +2.6%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Jul 30, 2026 | −1.0% | +2.6% |
Next-quarter estimates, ratings and the NBIX chart are in the terminal.
Open the terminalFAQ
When is Neurocrine Biosciences's next earnings report?
Feb 11, 2027. The date comes from daily data and is corrected if the company moves it.
How did Neurocrine Biosciences stock react to the report?
Opening gap −1.0%, day's result +2.6%.
Did Neurocrine Biosciences's earnings grow?
Earnings per share rose 31% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.